Methods: To investigate the effect of Baicalin on DCs, we isolated DCs from bone marrow of B57BL/6. And we attempted to determine expression of surface molecules, antigen uptake capacity, cytokine production, and capacity to induce T-cell differentiation. DC surface molecules and antigen uptake were measured by flow cytometry using specific antibodies and dextran-FITC, respectively. In cytokine assay, intracellular cytokine was determined by flow cytometry and also cytokine production was measured by ELISA. To verify the T cell polarization, we isolated T cells from spleen of BALB/C mice and performed the mixed lymphocyte reaction, and the T cells were co-cultured with DCs.
Results: Baicalin was shown to significantly suppress the expression of surface molecules CD80, CD86, major histocompatibility complex (MHC) class I, and MHC class II as well as the levels of interleukin-12 production in lipopolysaccharide stimulated DCs. Moreover, baicalin-treated DCs showed an impaired induction of the T helper type 1 immune response and a normal cell-mediated immune response.
Conclusions: These findings provide important understanding of the immunopharmacological functions of baicalin and have ramifications for the development of therapeutic adjuvants for the treatment of DCs-related acute and chronic diseases.